Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats

Journal of Pharmacological Sciences

Volumn 127, Issue 3, 2015, Pages 362-369

  Yamazaki, Mayako ^a   Okabe, Mayuko ^a   Yamamoto, Noriyuki ^a   Yarimizu, Junko ^a   Harada, Katsuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

5 HT5A receptor; Cognitive impairment; Occupancy; Water maze; Y maze

Indexed keywords

AS 2030680; AS 2674723; ASP 5736; LIGAND; LYSERGIDE; SCOPOLAMINE; SEROTONIN 5A RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; GUANIDINE DERIVATIVE; ISOQUINOLINE DERIVATIVE; N-(DIAMINOMETHYLENE)-1-(3,5-DIFLUOROPYRIDIN-4-YL)-4-FLUOROISOQUINOLINE-7-CARBOXAMIDE; SCOPOLAMINE BROMIDE; SEROTONIN 5 RECEPTOR; SEROTONIN RECEPTOR;

ADULT; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DRUG STRUCTURE; HIPPOCAMPUS; MALE; MEMORY; MEMORY DISORDER; MOUSE; NONHUMAN; OLFACTORY BULB; RAT; REFERENCE MEMORY IMPAIRMENT; SCHIZOPHRENIA; SCOPOLAMINE INDUCED WORKING MEMORY DEFICIT; WORKING MEMORY; YOUNG ADULT; AGING; ANIMAL; BRAIN; CHEMICALLY INDUCED; COGNITION DISORDERS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; INBRED MOUSE STRAIN; MAZE TEST; MEMORY DISORDERS; METABOLISM; PSYCHOLOGY; WISTAR RAT;

AGING; ANIMALS; BRAIN; COGNITION DISORDERS; DEMENTIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANIDINES; ISOQUINOLINES; LYSERGIC ACID DIETHYLAMIDE; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE, INBRED STRAINS; OLFACTORY BULB; RATS, WISTAR; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SCOPOLAMINE HYDROBROMIDE; SEROTONIN ANTAGONISTS;

EID: 84936877697     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2015.02.006     Document Type: Article

References (28)

1. 5A serotonin receptor. FEBS Lett. 1994;355:242-246.
2. 5A serotonin receptor mRNA in the human brain. Mol Brain Res. 1998;56:1-8.
3. 5A receptor-like immunoreactivity in the rat brain. Brain Res. 2000;867:131-142.
4. Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D, et al. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT (5A) receptor. Neuron. 1999;22(3):581-591.
5. 5A gene in depression, psychosis and antipsychotic response. NeuroReport. 2000;11:2017-2020.
6. Iwata N, Ozaki N, Inada T, Goldman D. Association of a 5-HT5A receptor polymorphism, Pro15Ser, to schizophrenia. Mol Psychiatry. 2001;6:217-219.
7. 5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia. Eur Neuropsychopharmacol. 2014;24:1698-1708.
8. Maurice T, Privat A. SA4503, a novel cognitive enhancer with [sigma]1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur J Pharmacol. 1997;328:9-18.
9. Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, et al. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1, 2, 4-triazol-4-yl]-2, 1, 3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur J Pharmacol. 2012;685(1-3):59-69.
10. Mandel RJ, Gage FH, Thal LJ. Enhanced detection of nucleus basalis magnocellularis lesion-induced spatial learning deficit in rats by modification of training regimen. Behav Brain Res. 1989;31:221-229.
11. Yamazaki M, Matsuoka N, Maeda N, Kuratani K, Ohkubo Y, Yamaguchi I. FR121196, a potential anti-dementia drug, ameliorates the impaired memory of rat in the Morris water maze. J Pharmacol Exp Ther. 1995;272:256-263.
12. Yamazaki M, Matsuoka N, Maeda N, Ohkubo Y, Yamaguchi I. FR960 N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a noval mechanism of action. J Pharmacol Exp Ther. 1996;279:1157-1173.
13. Thomas DR. 5-ht5A receptors as a therapeutic target. Pharmacol Ther. 2006;111:707-714.
14. Sarter M, Bodewitz G, Stephens DN. Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl). 1988;94:491-495.
15. 5 receptor reveals a remarkable heterogeneity within the 5HT1D receptor family. EMBO J. 1992;11:4779-4786.
16. Matthea H, Boschert U, Amlaiky N, Grailhe R, Plassat JL, Muscatejli F, et al. Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993;43:313-319.
17. Erlander MG, Lovenberg TW, Baron BM, de Lecea L, Danielson PE, Racke MAL, et al. Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc Natl Acad Sci U S A. 1993;90:3452-3456.
18. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm. 2006;113:1625-1644.
19. 5A antagonists, like atypical antipsychotics, increase acetylcholine release in medial prefrontal cortex of freely-moving rats. In: 36th Annu. Meet. Soc. Neurosci.; 2006 (October 14-18, Atlanta. USA), Abst.33.2.
20. Ingram DK, London ED, Goodrick CL. Age and neurochemical correlates of radial maze performance in rats. Neurobiol Aging. 1981;2:41-47.
21. Goldman-Rakic PS, Brown RM. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience. 1981;6:177-187.
22. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology. 1994;116:143-151.
23. Moore TL, Schettler SP, Killiany RJ, Herndon JG, Luebke JI, Moss MB, et al. Cognitive impairment in aged rhesus monkeys associated with monoamine receptors in the prefrontal cortex. Behav Brain Res. 2005;160:208-221.
24. Matsuoka N, Maeda N, Yamazaki M, Ohkubo Y, Yamaguchi I. Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks. J Pharmacol Exp Ther. 1992;263:436-444.
25. Packard MG, White NM. Memory facilitation produced by dopamine agonists: role of receptor subtype and mnemonic requirements. Pharmacol Biochern Behav. 1989;33:511-518.
26. Ichihara K, Nabeshima T, Kameyama T. Opposite effects induced by low and high doses of apornorphine on single-trial passive avoidance learning in mice. Pharmacol Biochem Behav. 1988;30:107-113.
27. Williams GV, Castner SA. Under the curve critical issue for elucidating D1 receptor function in working memory. Neuroscience. 2006;139:263-276.
28. Takizawa R, Tochigi M, Kawakubo Y, Marumo K, Sasaki T, Fukuda M, et al. Association between catechol-O-methyltrasferase Val108/158Met genotype and prefrontal hemodynamic response in schizophrenia. PLoS One. 2009;4(5):e5495.